EFFEKTIVNOST' GEPTRALA® V LEChENII PEChENOChNOY TOKSIChNOSTI, OBUSLOVLENNOY TsITOSTATIChESKOY KhIMIOTERAPIEY


Cite item

Full Text

Abstract

У 19 пациентов с различными злокачественными опухолями проведена оценка эффективности препарата Гептрал® (адеметионин) при лечении гепатотоксичности, индуцированной химиотерапией. Показано, что при 4-недельном приеме Гептрала® внутрь по 400 мг 2 раза в день уровень трансаминаз снизился до нормы у 10 из 12 пациентов с 1-й степенью гепатотоксичности. Для нормализации уровня трансаминаз при 2-й степени гепатотоксичности потребовался более длительный прием Гептрала® (от 2 до 4 месяцев). Режим химиотерапии в период применения Гептрала® не менялся.

About the authors

A V Snegovoy

L V Manzyuk

References

  1. King PD, Perry MC. Hepatoioxiciry of chemotherapy. The Oncologist 2001;6:162-76.
  2. DeLeve LD, Kaplovitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:787-810.
  3. Dansette PM, Bonierbale E, Minoletti С, et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23:443-51.
  4. Kaplowitz N, Aw TY, Simon FR et al. Drug-induced hepatotoxicity. Ann Intern Med 1986;104:826-39.
  5. Ishak KG, Zimmerman HJ. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:759-86.
  6. Larrey D. Drug-induced liver diseases. J Hepatol 2000;32:77-88.
  7. Zorti D, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surgery 2007;94:274-86.
  8. Paul D, et al. Hepatotoxicity of chemotherapy. The Oncologist 2001;6:162-76.
  9. O' Grady JG. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997;26:41-46.
  10. Strieker BH. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier, 1992.
  11. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford University Press 1999;2:1261-315.
  12. Hirata F, Viveros OH, Diliberto EJ. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci USA 1978;75:1718-21.
  13. Kretzschmar M, Klinger W. The hepatic glutathione system influences of xenobiotics. Exp Pathol 1990;38:145-64.
  14. Cabrero C, Duce AM, Ortiz P, et al. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988;8:1530-34.
  15. Cantoni GL. The nature of the active methyl donor formed enzymically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74:2942-43.
  16. Dunne JB, Davenport M, Williams R, et al: Evidence that S-adenosylmethionine and N-acetylcysteine reduce injury from sequential cold and warm ischaemia in the isolated perfused rat liver. Transplantation 1994;57:1161-68.
  17. Mato JM, Camara J, Fernandez de Paz J, et al. Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-89.
  18. Giudici GA, Le Grazie С, Di Padova C. The use of ademethionine (SAMe) in the treatment of cholestatic liver disorders: meta-analvsis of clinical trials. Methionine Metabolism: Molecular Mechanism and Clinical Implications. Madrid: CSIC Press pp 1992;67-9.
  19. Feliu J, Mel JR, Camps C, et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. An active and low toxicity regimen. Eur J Cancer 2002;З8:1204-11.
  20. Cascinu S, Graziano F, Ferrau F, et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13:716-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies